Metrics as of 10/15/2026, 11:44 AM (Berlin time), refresh in progress.
Assembly Biosciences Stock
Assembly Biosciences, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Jason A. Okazaki
- Employees
- 73
- Market cap
- $418 M
- IPO
- 17/12/2010
Assembly Biosciences, Inc. is a biotechnology firm in the clinical development phase, dedicated to identifying and advancing innovative therapeutic solutions for hepatitis B virus (HBV) infections within the United States. Its primary drug candidate, Vebicorvir, has successfully concluded Phase 2 clinical trials for…
Assembly Biosciences stock: price history
1D
+0.9%
1W
-10.5%
1M
-29.1%
6M
-31.1%
YTD
-39.6%
1Y
-27.7%
2Y
+20.7%
5Y
-47.5%
10Y
-85.3%
Next earnings date
Next earnings date
09/11/2026 (in 23 days)
Volatility around earnings
~17% weaker price swings than usual
Pattern chart
Pattern detected by the Market Jury detector vdouble-bottom-top-v1.0 on 13/10/26. Not a buy or sell signal.Beta
What does this mean?
Double top
BearishThe price failed at a similar high twice, with a pullback in between. This M-shaped pattern is a classic reversal signal from an uptrend into a downtrend.
Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.
Ask the agents about Assembly Biosciences
Analyst assessment of Assembly Biosciences
PRICE TARGET LOW
US$50.00
CONSENSUS
US$51.67
MEDIAN
US$52.00
PRICE TARGET HIGH
US$53.00
0
STRONG BUY
6
BUY
5
HOLD
0
SELL
0
STRONG SELL
11
TOTAL · Buy
As of: 01/09/2026
Assembly Biosciences stock metrics
P/E
37.33
P/B
1.27
EV/EBITDA
5,706.87
RETURN ON EQUITY
-1.3%
NET MARGIN
-28.8%
DEBT/EQUITY
0.01
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
71.6%
FLOAT SHARES
14,585,173
AVG. DAILY VOLUME (30D)
345,968
Insider transactions (SEC)
Bjorkquist Jeanette M
Okazaki Jason A
Delaney William E IV
Bjorkquist Jeanette M
White Nicole S
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Assembly Biosciences stock
What does Assembly Biosciences do?
Assembly Biosciences, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Jason A. Okazaki, the company employs around 73 people.
The IPO was on 17/12/2010; the stock trades on NASDAQ under the ticker ASMB.
What do analysts say about Assembly Biosciences stock?
11 analysts rate the stock, the consensus is Buy (as of 01/09/2026).
The average price target is US$51.67, ranging from US$50.00 to US$53.00, with a median of US$52.00.
This is an external assessment, not a statement by Market Jury.
When does Assembly Biosciences report next?
The next earnings date is 09/11/2026.
Around past earnings, price swings were roughly -17% stronger than usual.
Does Assembly Biosciences pay a dividend?
No, Assembly Biosciences currently does not pay a dividend.
Which stocks are comparable to Assembly Biosciences?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Assembly Biosciences stock analyzed?
Clicking "Analyze stock" lets five strategies assess Assembly Biosciences against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.